VSTM
Verastem, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.62
−0.35%Year over year
Reported trailing growth
- Revenue
- +3995.7%
- EBITDA
- -22.0%
- EBIT
- -2.1%
- EPS
- +32.6%
- Free cash flow
- -36.0%
- Operating cash flow
- -34.9%
Forward estimates
Based on analyst estimates
- Revenue
- +80.2%
- EBITDA
- -3.9%
- EPS
- +14.6%
Three-year CAGR
- Revenue
- +128.4%
- EBITDA
- -64.9%
- EBIT
- -48.0%
- Net income
- -60.3%
- EPS
- +17.5%
- Free cash flow
- -31.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026